Stockscreener 앱 받기
0.46
0.00%
0.00
전일 마감가:
$0.46
열려 있는:
$0.46
하루 거래량:
140.71K
Relative Volume:
0.71
시가총액:
$12.63M
수익:
$5.61M
순이익/손실:
$-55.45M
주가수익비율:
-0.179
EPS:
-2.5703
순현금흐름:
$-42.35M
1주 성능:
-7.89%
1개월 성능:
-17.86%
6개월 성능:
-46.20%
1년 성능:
-68.92%
1일 변동 폭
$0.46
$0.475
1주일 범위
$0.4501
$0.51
52주 변동 폭
$0.4501
$2.19
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
명칭
Citius Pharmaceuticals Inc
전화
(908) 967-6676
주소
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.46 | 12.63M | 5.61M | -55.45M | -42.35M | -2.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스
Azitra advances ATR04-484 trial for cancer trea... - Pluang
Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com Canada
Citius Pharmaceuticals at Moody Capital conference: launch gains traction - Investing.com
CTXR: LYMPHIR launch drives early revenue and creates an investment arbitrage opportunity - TradingView
Citius Pharmaceuticals stock stabilizes as investors look to next data catalysts - ad-hoc-news.de
CTXR Stock Price, Quote & Chart - ChartMill
Citius Pharma CEO to speak at two New York conferences - Stock Titan
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire
Citius Pharmaceuticals Inc. Warrant (CTXRW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Citius Pharmaceuticals Inc. Warrant (CTXRW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Citius Pharmaceuticals Inc. (CTXR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
CITIUS ONCOLOGY, INC. SEC Filing (Aug 26, 2026) - Stock Titan
Citius (CTXR) Earnings Report: Reported EPS Misses Expectations in the Latest Reading; Price Reaction: Shares Move 0.07% Higher in the Current UpdateFinal Results - vinanet.vn
Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq gives Citius (NASDAQ: CTXR) more time before $1 delisting risk - Stock Titan
H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citius (CTXR) Market-Day Review: Finishes 1.78% Higher at $0.57 in the Latest Session; Key Levels: the Near-Term Reference Band Stretches From $0.54 to $0.60 in the Available RecordWMA Signal - vinanet.vn
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance
Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Clinical Focus Checkpoint Mean? - Kalkine Media
Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Program Priorities Checkpoint Mean? - Kalkine Media
Is Citius Pharmaceuticals (CTXR) Worth the Investment After Q3 E - GuruFocus
CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% While Stock Gains 3.0%Analyst Earnings Estimate - vinanet.vn
Citius Pharmaceuticals (CTXR) Gains 3% to $0.76 as Buyers Defend SupportBull Pennant - dars.gov.et
Citius Pharmaceuticals (CTXR) Gains 3% to $0.76 as Buyers Defend SupportTriple EMA - vinanet.vn
Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard
Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - minichart.com.sg
Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan
Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - The AI Journal
Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI
CTXR: LYMPHIR's launch drove $7.1M revenue and 77% gross margin, offset by higher launch costs - TradingView
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Citius Oncology, Inc. Announces Appointment of Jonathan Peri, Ph.D., J.D., as Independent Director, Effective August 10, 2026 - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan
CTXR Q3'26 Earnings: EPS estimate is (0.36) USD - TradingView
Citius Oncology appoints independent director Peri to board of directors - ROI-NJ
People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar
Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union
Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz
Citius Oncology appoints Jonathan Peri to board of directors - Investing.com
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - PR Newswire
Citius Pharmaceuticals (CTXR) Edges Higher by 1.92%, Maintaining Position Above Key Support at $0.69TWAP Entry - vinanet.vn
BREAKING: THE PRINTING HAS STARTED! Robert De Niro (xWXxQcdGpe) - Mshale
CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% as Shares Rise 6.23%Banking Earnings Report - vinanet.vn
CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% as Shares Rise 6.23%ROE Trend Analysis - dars.gov.et
CTXR Q4 2025 Earnings: Bigger-Than-Expected Loss Meets 6.23% Share RallyEarnings Sentiment Score - careplusvn.com
Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Pharmaceuticals Inc (CTXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):